Rezazadeh H, Amjadi O, Rostamkolaei A S, Alizadeh Forutan M, Eslami-Jouybari M, Alizadeh-Navaei R, et al . Association between Serum Transthyretin Levels and
Gastric Cancer. J Mazandaran Univ Med Sci 2021; 31 (202) :88-95
URL:
http://jmums.mazums.ac.ir/article-1-17266-en.html
Abstract: (1913 Views)
Background and purpose: Gastric adenocarcinoma is the fifth most common cancer and the fourth leading cause of cancer death in both men and women. Transthyretin (TTR) is a useful marker for cancer diagnosis and prediction in patients undergoing surgery. The diagnostic value of this biomarker in gastric cancer has not yet been determined conclusively. This investigation aimed at studying the diagnostic role of serum TTR in patients with gastric cancer.
Materials and methods: This case-control study, was performed in 40 patients whose gastric cancer was confirmed pathologically and 42 healthy individuals without family history of gastrointestinal and liver cancers. The sandwich prepared ELISA kit was used to determine the concentration of transthyretin protein produced in serum.
Results: The mean age of patients with gastric cancer was 63 ± 13 years and the mean age of the control group was 64 ± 16 years (P= 0.681). The mean serum concentrations of transthyretin in patients and healthy people were 138.45 ± 49.64 pg/mL and 113.53 ± 60.12 pg/mL, respectively. Findings showed a significant difference in serum transthyretin levels between the two groups (P= 0.045). Therefore, TTR could be used as a diagnostic marker.
Conclusion: In this study, serum levels of transthyretin were significantly higher in patients with gastric cancer than healthy individuals.